Abstract:e21646 Background: Identifying targetable genetic variants may help maximize clinical benefit of non-small cell lung cancer (NSCLC). Here, we retrospectively analyzed the benefit of next-generation sequencing (NGS) for NSCLC in routine clinical practice. Methods: A total of 59 NSCLC patients were enrolled in the study from Jun. 2018 to Dec. 2019. Formalin-fixed paraffin-embedded tissues samples were collected and sequenced by NGS, which detects single-nucleotide variants, small insertions/deletions, rearrangements, and copy-number alterations of either 59 or 1021 tumor related genes. The tumor response was evaluated using RECIST v1.1. Results: The detection rate of targetable variants was 59.32% (35/59), including EGFR mutation 49.15% (29/59), ALK rearrangement 5.08% (3/59), ROS1 rearrangement 1.69% (1/59), BRAF V600E mutation 1.69% (1/59), and ERBB2 mutation 1.69% (1/59). Of 29 patients with EGFR mutations, 5 patients (17.24%) had multiple EGFR mutations, including 2 patients (6.89%) with uncommon mutations. 25patients (86.21%) harbored concurrent mutations that may limit the efficacy of EGFR-TKIs, including EGFR amplification, activation of bypass signaling pathways, TP53 exon8 mutation, BCL2L11 deletion polymorphism, and PI3K-AKT-mTOR and cell cycle gene alterations. Among 25 patients received EGFR-TKIs, TKI effectiveness was evaluated in 18 patients. The disease control rate was 100% and overall response rate was 27.78%. The proportion of patients with TMB-H and/or PD-L1≥1, and targetable variants negative was 33.89% (20/59). Only one patient of this group received immunotherapy with pembrolizumab and achieved SD at the 2 nd month. The proportion of patients with targetable variants negative, TMB-L, and PD-L1 < 1 or unknow patients was 6.78% (4/59), two patients of them left hospital without additional treatment, two patients received chemotherapy and the KRAS mutation present in one of them suggested that he might be resistant to EGFR-TKIs. Conclusions: More than half of NSCLC patients have targetable genetic variants and more than 30% patients have a molecular signature that can be treated with immunotherapy. Compared with immunotherapy, targeted therapy has higher acceptability in real-world. NGS-based genetic testing may have clinical value to predict the effectiveness of targeted therapy and immunotherapy. It can be widely implemented and standardized into clinical use.

Synchronous Non-Small Cell Lung Cancers: Diagnostic Yield Can Be Improved by Histologic and Genetic Methods

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Immunohistochemistry combined with NGS to assist the differential diagnosis of multiple primary lung cancer with lymph node metastasis: a case report

Using molecular characteristics to distinguish multiple primary lung cancers and intrapulmonary metastases

Favorable prognosis and high discrepancy of genetic features in surgical patients with multiple primary lung cancers.

Genomic Heterogeneity of Multiple Synchronous Lung Cancer

Clinical and CT characteristics for predicting lymph node metastasis in patients with synchronous multiple primary lung adenocarcinoma

Identification and Validation of the Methylation Biomarkers of Non-Small Cell Lung Cancer (NSCLC).

Genomic heterogeneity of multifocal NSCLC.

Identifying The Clonal Origin Of Synchronous Multifocal Tumors In The Hepatobiliary And Pancreatic System Using Multi-Omic Platforms

High Sensitive and Non-invasive Ctdnas Sequencing Facilitate Clinical Diagnosis and Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study

Longitudinal detection of subcategorized CD44v6 + CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study

Integrated Molecular Portrait of Non-Small Cell Lung Cancers.

Molecular features of NSCLC patients with liver metastasis

Advances in novel molecular typing and precise treatment strategies for small cell lung cancer

Survival rate and prognostic factors of surgically resected clinically synchronous multiple primary non-small cell lung cancer and further differentiation from intrapulmonary metastasis.

Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer-A Single-Center Experience

A Rare Case of Synchronous Multiple Primary Lung Cancer: Squamous Cell Cancer and Small Cell Lung Cancer

Identification of Vital Genes for NSCLC Integrating Mutual Information and Synergy